Basilea Pharmaceutica AG (BPMUF)
USD 52.83
(0.0%)
USD 52.83
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 10.45 Million CHF | -13.96% |
| 2022 | 12.14 Million CHF | 277.82% |
| 2021 | -6.83 Million CHF | 53.6% |
| 2020 | -14.72 Million CHF | 34.34% |
| 2019 | -22.42 Million CHF | 28.48% |
| 2018 | -31.35 Million CHF | -61.94% |
| 2017 | -19.36 Million CHF | 62.25% |
| 2016 | -51.28 Million CHF | 16.75% |
| 2015 | -61.6 Million CHF | -48.28% |
| 2014 | -41.54 Million CHF | -25.82% |
| 2013 | -33.01 Million CHF | 37.74% |
| 2012 | -53.03 Million CHF | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 10.36 Million CHF | 148.48% |
| 2024 Q2 | 10.36 Million CHF | 0.0% |
| 2023 Q1 | 15.92 Million CHF | -34.64% |
| 2023 Q4 | -21.38 Million CHF | -100.0% |
| 2023 Q3 | -10.69 Million CHF | -133.59% |
| 2023 Q2 | 31.84 Million CHF | 100.0% |
| 2023 FY | 10.45 Million CHF | -13.96% |
| 2022 Q1 | -6.1 Million CHF | -146.74% |
| 2022 Q4 | 24.35 Million CHF | 100.0% |
| 2022 Q3 | 12.17 Million CHF | 199.75% |
| 2022 Q2 | -12.2 Million CHF | -100.0% |
| 2022 FY | 12.14 Million CHF | 277.82% |
| 2021 Q2 | -19.89 Million CHF | -100.0% |
| 2021 Q4 | 13.06 Million CHF | 100.0% |
| 2021 FY | -6.83 Million CHF | 53.6% |
| 2021 Q1 | -9.94 Million CHF | 59.67% |
| 2021 Q3 | 6.53 Million CHF | 132.83% |
| 2020 FY | -14.72 Million CHF | 34.34% |
| 2020 Q1 | 4.97 Million CHF | 171.1% |
| 2020 Q4 | -24.66 Million CHF | -100.0% |
| 2020 Q2 | 9.94 Million CHF | 100.0% |
| 2020 Q3 | -12.33 Million CHF | -224.05% |
| 2019 FY | -22.42 Million CHF | 28.48% |
| 2019 Q4 | -6.99 Million CHF | -100.0% |
| 2019 Q1 | -7.71 Million CHF | -75.25% |
| 2019 Q3 | -3.49 Million CHF | 77.35% |
| 2019 Q2 | -15.43 Million CHF | -100.0% |
| 2018 FY | -31.35 Million CHF | -61.94% |
| 2018 Q3 | -4.4 Million CHF | 60.95% |
| 2018 Q2 | -11.27 Million CHF | 0.0% |
| 2018 Q1 | -11.27 Million CHF | -1972.67% |
| 2018 Q4 | -4.4 Million CHF | 0.0% |
| 2017 Q1 | -10.28 Million CHF | 11.99% |
| 2017 Q4 | 602 Thousand CHF | 0.0% |
| 2017 FY | -19.36 Million CHF | 62.25% |
| 2017 Q2 | -10.28 Million CHF | 0.0% |
| 2017 Q3 | 602 Thousand CHF | 105.85% |
| 2016 Q2 | -13.96 Million CHF | 0.0% |
| 2016 Q3 | -11.68 Million CHF | 16.31% |
| 2016 Q4 | -11.68 Million CHF | 0.0% |
| 2016 FY | -51.28 Million CHF | 16.75% |
| 2016 Q1 | -13.96 Million CHF | 11.33% |
| 2015 FY | -61.6 Million CHF | -48.28% |
| 2015 Q3 | -15.74 Million CHF | -4.55% |
| 2015 Q2 | -15.05 Million CHF | 0.0% |
| 2015 Q1 | -15.05 Million CHF | -36.17% |
| 2015 Q4 | -15.74 Million CHF | 0.0% |
| 2014 Q2 | -9.71 Million CHF | 0.0% |
| 2014 FY | -41.54 Million CHF | -25.82% |
| 2014 Q4 | -11.05 Million CHF | 0.0% |
| 2014 Q3 | -11.05 Million CHF | -13.82% |
| 2014 Q1 | -9.71 Million CHF | -23.48% |
| 2013 Q3 | -7.86 Million CHF | 8.97% |
| 2013 FY | -33.01 Million CHF | 37.74% |
| 2013 Q4 | -7.86 Million CHF | 0.0% |
| 2013 Q2 | -8.64 Million CHF | 0.0% |
| 2013 Q1 | -8.64 Million CHF | 6.39% |
| 2012 FY | -53.03 Million CHF | 0.0% |
| 2012 Q3 | -9.23 Million CHF | 0.0% |
| 2012 Q4 | -9.23 Million CHF | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 113.942% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 258.924% |
| SQZ Biotechnologies Company | -79.46 Million USD | 113.152% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 80.273% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 83.954% |
| Mesoblast Limited | -87.95 Million USD | 111.882% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 674.064% |
| Genus plc | 7.9 Million USD | -32.291% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 195.953% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 381.68% |
| Marizyme, Inc. | -65.34 Million USD | 115.993% |
| ContraFect Corporation | -65.15 Million USD | 116.041% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 218.171% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 313.894% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 704.994% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 461.327% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 229.67% |
| MultiCell Technologies, Inc. | -380.07 USD | 2749856.624% |
| Accustem Sciences Inc. | -3.74 Million USD | 378.96% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 120.218% |
| EV Biologics, Inc. | -1.26 Million USD | 924.775% |
| Q BioMed Inc. | -2.05 Million USD | 609.285% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 379.962% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 1752.575% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 538.957% |
| Biomind Labs Inc. | -1.21 Million USD | 960.647% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 199.08% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 232.239% |
| Skye Bioscience, Inc. | -37.64 Million USD | 127.762% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 581.654% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 69884.989% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 249.667% |
| IMV Inc. | -36.48 Million USD | 128.644% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 165.848% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 279.655% |
| GB Sciences, Inc. | -1.36 Million USD | 867.509% |
| Alpha Cognition Inc. | -13.77 Million USD | 175.883% |
| HST Global, Inc. | -146.21 Thousand USD | 7247.938% |
| CSL Limited | 2.64 Billion USD | 99.604% |
| Halberd Corporation | -79.67 Thousand USD | 13216.873% |
| Enzolytics Inc. | -2.17 Million USD | 580.101% |
| Resverlogix Corp. | -3.61 Million USD | 389.501% |
| Affymax, Inc. | -14.42 Million USD | 172.456% |
| SYBLEU INC | -180.3 Thousand USD | 5896.322% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 429.535% |
| argenx SE | -295.05 Million USD | 103.542% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 116.695% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -10564.286% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 363.051% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 445.358% |
| AVAX Technologies, Inc. | -6.41 Million USD | 262.949% |
| Zenith Capital Corp. | -10.59 Million USD | 198.632% |
| Genscript Biotech Corporation | -95.47 Million USD | 110.946% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 45066.01% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 352.078% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 17391.354% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 117.498% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 436.937% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | 1089.625% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 636.155% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 373.658% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 621.217% |
| BioStem Technologies, Inc. | -8.48 Million USD | 223.2% |
| ONE Bio Corp. | 8.67 Million USD | -20.45% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 2467.86% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 882.594% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 695.576% |
| Agentix Corp. | -1.37 Million USD | 860.509% |
| LadRx Corporation | 400.44 Thousand USD | -2509.86% |
| Cell Source, Inc. | -5.32 Million USD | 296.403% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 2615.41% |
| Regen BioPharma, Inc. | 1.02 Million USD | -921.096% |
| Regen BioPharma, Inc. | 1.02 Million USD | -921.096% |
| NovAccess Global Inc. | -4.76 Million USD | 319.136% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -50.926% |
| Itoco Inc. | -1.86 Million USD | 659.178% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 335.249% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 726.183% |
| Kadimastem Ltd | -3.3 Million USD | 415.989% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 3922.576% |
| CytoDyn Inc. | -49.84 Million USD | 120.969% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 13323.59% |
| Mobile Lads Corp. | -2.26 Million USD | 561.761% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 4681.22% |
| Qrons Inc. | -789.34 Thousand USD | 1424.006% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 1210.003% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 600.603% |
| Rebus Holdings, Inc. | -1.02 Million USD | 1124.608% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 748.029% |
| International Stem Cell Corporation | -131 Thousand USD | 8077.863% |
| Bioxytran, Inc. | -4.28 Million USD | 344.182% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 19356.707% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 513.043% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 121.74% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 594.371% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 1438.35% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 429.893% |
| Neutra Corp. | -233.46 Thousand USD | 4576.474% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 151.506% |
| PureTech Health plc | -65.69 Million USD | 115.908% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 149.143% |
| IXICO plc | -1.17 Million USD | 987.182% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 205.279% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 118.294% |
| CSL Limited | 2.64 Billion USD | 99.604% |
| Cellectis S.A. | -103.17 Million USD | 110.13% |